High Prevalence and Clinical Nuance of JAKne in IBD Management
The landscape of therapeutic options for inflammatory bowel disease (IBD) has been significantly transformed by the introduction of Janus Kinase (JAK) inhibitors. While these small molecules offer rapid and effective control of mucosal inflammation, they are associated with a unique profile of adverse events. Among these, JAK inhibitor-induced acne—frequently termed ‘JAKne’—has emerged as a common but often underestimated dermatological complication. A landmark international, multicenter study published in Clinical Gastroenterology and Hepatology provides the most comprehensive data to date on the epidemiology, risk factors, and clinical consequences of this condition.
